Market Research Logo

Global Phosphate Binder (Hyperphosphatemia) Market: Industry Analysis & Outlook (2019-2023)

Global Phosphate Binder (Hyperphosphatemia) Market: Industry Analysis & Outlook (2019-2023)

Phosphate binder also referred as phosphorus binder, is a medication prescribed to reduce the absorption of dietary phosphate and to control the amount of phosphorus in the blood. They are frequently used by people with chronic kidney failure, who are not able to excrete phosphate and causing a high level of phosphate level in the body. Phosphate binders bind phosphate and are then excreted from the body.

Phosphate binders such as aluminum-based antacids, magnesium-based antacids, calcium carbonate, calcium acetate, sevelamer, and lanthanum are essential for patients whose phosphorus levels stay high despite dietary restrictions. Controlling phosphate level is important as it is associated with bone pathology and accompanied with elevated calcium level by the parathyroid hormone.

The global phosphate binder market is driven by an increasing aging population as well as the rising prevalence of chronic kidney diseases. The drugs, namely Velphoro, Auryxia, PhosLo, and Renegal are expected to show high growth prospects in the coming years. Since a large part of the population suffers from kidney diseases, the chances of developing end-stage renal failure have increased to a large extent, thereby propelling the growth of the market during the forecasted period.

With the advancements in the healthcare infrastructure in the U.S., the phosphate binder medication growth is estimated to continue and thereby, making this region a potential opportunity for manufacturers. The number of treated population is also rising owing to increase in awareness regarding treatment.

The report “Global Phosphate Binder Market: Industry Analysis & Outlook (2019-2023)” by Koncept Analytics provides extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the United States, Europe, and Japan regions along with the global market. The report profiles the key players of the market including AMAG Pharmaceuticals, Inc., Vifor Pharma Ltd., Sanofi S.A., and Akebia Therapeutics Inc.


1. Market Overview
1.1 Chronic Kidney Disease (CKD)
Table 1: Stages of CKD
Table 2: Renoprotective Strategies for Slowing Progression of CKD
1.2 Hyperphosphatemia
Table 3: Phosphate Management in Chronic Kidney Disease
1.3 Phosphate Binder
Table 4: Types of Phosphate Binders
1.4 Phosphate Binder Products
Table 5: Administration of Currently Approved Phosphate Binders
2. Global Phosphate Binder Market
2.1 Global Phosphate Binders Drugs in Development
Table 6: Global Phosphate Binders Drugs in Development (2018)
2.2 Global Phosphate Binder Prescription Market Share
Table 7: Global Phosphate Binder Prescription Market Share (Dec 2017- May 2018)
2.3 Global Sevelamer Revenue
Table 8: Global Sevelamer Revenue (2014-2018)
2.4 Global Sevelamer Prescription Market Share by Brand
Table 9: Global Sevelamer Prescription Market Share by Brand (Dec 2017- May 2018)
2.5 Auryxia Prescription and Tablets Count
Table 10: Auryxia Prescription and Tablets Count (2017-2018)
2.6 Global Velphora Revenue Forecast
Table 11: Global Velphora Revenue Forecast (2018-2023)
3. Regional Markets
3.1 The U.S.
3.1.1 The U.S. Dialysis Patients on Phosphate Binder Forecast
Table 12: The U.S. Dialysis Patients on Phosphate Binder Forecast (2018-2023)
3.1.2 The U.S. Peritoneal Dialysis Patients on Phosphate Binder Forecast
Table 13: The U.S. Peritoneal Dialysis Patients on Phosphate Binder Forecast (2018-2023)
3.1.3 The U.S. Auryxia Revenue and Penetration Forecast
Table 14: The U.S. Auryxia Revenue and Penetration Forecast (2018-2023)
3.1.4 The U.S. Velphoro Revenue Forecast
Table 15: The U.S. Velphoro Revenue Forecast (2018-2023)
3.2 Europe
3.2.1 Europe Phosphate Binder Treated Population Forecast
Table 16: Europe Phosphate Binder Treated Population Forecast (2018-2023)
3.2.2 Europe Velphoro Revenue Forecast
Table 17: Europe Velphoro Revenue Forecast (2018-2023)
3.3 Japan
3.3.1 Japan Phosphate Binder Treated Population Forecast
Table 18: Japan Phosphate Binder Treated Population Forecast (2018-2023)
3.3.2 Japan Velphoro Revenue Forecast
Table 19: Japan Velphoro Revenue Forecast (2018-2023)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Aging Population
Table 20: Global Aging Population (2014-2018)
4.1.2 Increasing Healthcare Spending
Table 21: Global Healthcare Spending Per Capita (2014-2018)
4.1.3 Increasing Cases of ESRD
Table 22: Global ESRD Patients (2014-2018)
4.1.4 Increasing Life Expectancy
Table 23: Life Expectancy at Birth (2014-2018)
4.1.5 High Unmet Medical Needs
4.2 Key Trends & Developments
4.2.1 Increasing Demand for Effective Phosphate Binder Treatment
Table 24: Phosphate Binder HD Share Over Time (Q1 2017-Q4 2018)
4.3 Challenges
4.3.1 Gastrointestinal Reactions Leading to Discontinuation
Table 25: Reasons for Brand Discontinuation (Q1 2019)
4.3.2 Entry of Generic Products
4.3.3 Regulatory Framework
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
Table 26: Key Players - Revenue & Market Cap Comparison (2018)
5.1.2 Research & Development Expenditure (as a % of Revenue) Comparison
Table 27: Key Players - Research & Development Expenditure (%) Comparison (2018)
5.1.3 Approved Phosphate Binders Dosage Comparison
Table 28: Approved Phosphate Binders Dosage Comparison (2018)
5.1.4 Approved Phosphate Binders Safety Comparison
Table 29: Approved Phosphate Binders Safety Comparison (2018)
5.1.5 Approved Phosphate Binders Shortcomings Comparison
Table 30: Approved Phosphate Binders Shortcomings Comparison (2018)
6. Company Profiles
6.1 AMAG Pharmaceuticals, Inc.
6.1.1 Business Overview
Table 31: AMAG Pharmaceuticals, Inc. Revenue by Segment (2018)
6.1.2 Financial Overview
Table 32: AMAG Pharmaceuticals, Inc. Revenue and Net Income (2014-2018)
6.1.3 Business Strategies
Table 33: AMAG Pharmaceuticals, Inc. R&D Expenditure (2016-2018)
6.2 Vifor Pharma Ltd.
6.2.1 Business Overview
Table 34: Vifor Pharma Net Sales by Product Brand (2018)
6.2.2 Financial Overview
Table 35: Vifor Pharma Net Sales and Net Profit (2014-2018)
6.2.3 Business Strategies
Table 36: Vifor Pharma R&D Expenditure (2016-2018)
6.3 Sanofi S.A.
6.3.1 Business Overview
Table 37: Sanofi S.A. Net Sales by Segment (2018)
6.3.2 Financial Overview
Table 38: Sanofi S.A. Net Sales and Net Income (2014-2018)
6.3.3 Business Strategies
Table 39: Sanofi S.A. R&D Expenditure (2016-2018)
6.4 Akebia Therapeutics Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
Table 40: Akebia Therapeutics Inc. Revenue and Net Loss (2014-2018)
6.4.3 Business Strategies
Table 41: Akebia Therapeutics Inc. R&D Expenditure (2016-2018)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report